sb 203580 and l 365260
sb 203580 has been researched along with l 365260 in 2 studies
Compound Research Comparison
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (l 365260) | Trials (l 365260) | Recent Studies (post-2010) (l 365260) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 422 | 10 | 8 |
Protein Interaction Comparison
| Protein | Taxonomy | sb 203580 (IC50) | l 365260 (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0081 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0081 | |
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | 0.4981 | |
| Gastrin/cholecystokinin type B receptor | Rattus norvegicus (Norway rat) | 0.039 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0081 | |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | 5 | |
| Cholecystokinin receptor type A | Homo sapiens (human) | 0.1585 | |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | 0.0079 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 5 | |
| Cholecystokinin receptor type A | Cavia porcellus (domestic guinea pig) | 0.044 | |
| Cysteinyl leukotriene receptor 2 | Homo sapiens (human) | 5 | |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | 5 |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bergé, G; Carnazzi, E; Gagne, D; Galleyrand, JC; Ibarz, G; Martinez, J; Morel, C; Oiry, C | 1 |
| Cao, J; Luo, HS; Ming, M; Song, WC; Yu, HG; Yu, JP; Zhou, YH | 1 |
Other Studies
2 other study(ies) available for sb 203580 and l 365260
| Article | Year |
|---|---|
Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and p38 MAP kinase.
Topics: Adenosine Triphosphate; Animals; Benzodiazepinones; Binding Sites; Blotting, Western; COS Cells; Devazepide; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genes, Reporter; Hormone Antagonists; Imidazoles; Immunoblotting; Inositol Phosphates; Kinetics; Ligands; MAP Kinase Signaling System; Models, Chemical; Models, Molecular; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Binding; Protein Conformation; Pyridines; Rats; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Signal Transduction; Time Factors; Transfection | 2005 |
[The role of p38 MAPK in gastrin-induced u-PA expression in human colon cancer cells].
Topics: Benzodiazepinones; Blotting, Western; Cell Line, Tumor; Colonic Neoplasms; Gastrins; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Imidazoles; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; Pyridines; Receptor, Cholecystokinin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transfection; Urokinase-Type Plasminogen Activator | 2007 |